

**From:** [REDACTED] (GROW)  
**To:** GAMBS Hubert (GROW); [REDACTED] (GROW); [REDACTED] (GROW); [REDACTED]  
[REDACTED]  
[REDACTED] JORNA Kerstin (GROW)  
**Cc:** GROW TFIS; [REDACTED]  
**Subject:** Flash report: Meeting with EFPIA 23/02/2021  
**Date:** mardi 23 février 2021 17:10:35  
**Attachments:** [Fwd follow-up on shortages of Biological products anticipated.msg](#)

---

Dear Hubert, dear colleagues,

Please find below my notes on today's meeting with EFPIA.

Best regards,

[REDACTED]

Participants:

EFPIA: [REDACTED]

DG GROW: Kerstin Jorna, Hubert Gambs, [REDACTED]

KJ asked EFPIA information on production capacity up till the end of the year as well as forecast of needs in terms of materials and ingredients. She confirmed that DG GROW was now responsible for the industrial pillar of the vaccine strategy and that our role was to support the industry in delivering for Europe and for the world. To do so we need:

- the list of products in high demand / for which there are shortages;
- scenarios for vaccine production in 2021 and 2022;
- facts and figures to help us decide where and when to act.

EFPIA confirmed that shortages of components are being noticed, these are being communicated to EMA (see attached e-mail with details).

The industry is concerned that the incredible ramp up in vaccines this year will have a more general impact in 2022, compromising the production of a numbers of biological drugs and vaccines.

EFPIA will conduct survey on raw materials for all biological production in order to clearly assess the consequences (rise in prices, tough choices in what to produce).

Agreed follow-up:

- EFPIA to send details of interaction with EMA (see e-mail attached and in particular mention to: raw materials and key components such as filters, single use technology bags, peptone, TRIS HCL, and glass vials).
- EFPIA to send results of survey.
- KJ to meet [REDACTED] (DG EMA).